Dialysis industry news

Stories from the dialysis comunity across the globe.



Gore® Hybrid Vascular Graft Honored as Gold Winner in the 2012 Medical ... - EON: Enhanced Online News (press release) PDF Print

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) today announced that the GORE® Hybrid Vascular Graft was awarded Gold Winner in the Implant and Tissue-Replacement Products category of the 2012 Medical Design Excellence Awards (MDEA) competition. The Gore Device is an expanded polytetrafluoroethylene (ePTFE) vascular prosthesis that provides a streamlined solution for challenging dialysis access, aortic debranching, and arterial bypass procedures. The award-winning prosthesis provides a new way in for better outflow and the potential to significantly improve patient outcomes.

“This is a golden win and an example of our commitment to providing superior performance through design”

The MDEA winners were selected through a comprehensive review by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, clinical practice, diagnostics, human factors, industrial design, manufacturing, and medicine. Entries were evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges to meet its clinical objectives.

The GORE Hybrid Vascular Graft combines several trusted Gore technologies. The ePTFE vascular prosthesis has a section reinforced with nitinol that is partially constrained to allow for easy insertion and deployment into vessels that are difficult to reach or in challenging anatomical locations. It is the only combination graft that incorporates CARMEDA® BioActive Surface (CBAS® Surface) end-point immobilization of heparin to the luminal surface, resulting in a proven thromboresistant surface.

“This is a golden win and an example of our commitment to providing superior performance through design,” said Chuck Biggerstaff, associate with the Gore Venous Access Business. “The GORE Hybrid Vascular Graft is an innovative, versatile device that expands treatment options and improves patient outcomes.”

ABOUT W. L. GORE & ASSOCIATES

The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 30 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery. Gore was recently named one of the best companies to work for by Fortune magazine for the 15th consecutive year. For more information, visit www.goremedical.com.

Products listed may not be available in all markets. GORE® and designs are trademarks of W. L. Gore & Associates. CARMEDA® and CBAS® are trademarks of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates.

...

 
University of Louisville to partner with American Renal Associates for dialysis clinic. PDF Print
Nephrology News: University Medical Foundation Inc., a non-profit organization established to benefit the University of Louisville School of Medicine, has entered into a joint venture with American Renal Associates to form a new dialysis organization that provides services to people in the Louisville region. University Kidney Center LLC began operations July 1, and is conducting business as the University of Louisville Renal Dialysis Center. UMF will hold 30% equity in the new joint venture

...

 
DaVita settles allegations of improper billing for ESAs without admitting any wrongdoing. PDF Print
Marketwatch: DaVita Inc. today announced that it has reached an agreement in principle regarding all claims arising out of the previously disclosed litigation filed in 2002 in the U.S. District Court in the Eastern District of Texas. DaVita anticipates making repayments in the amount of $55 million plus attorneys fees as part of the settlement.

...

 
CMS proposes increasing payment to dialysis units by 3.1% PDF Print
CMS: In addition to other updates, payment rates for outpatient maintenance dialysis treatments are anticipated to increase by 2.5 percent in CY 2013. This reflects the ESRD bundled market basket increase of 3.2 percent reduced by a productivity adjustment of 0.7 percent, as required by statute. CMS estimates that Medicare payments to the 5,633 ESRD facilities in CY 2013 will total $8.7 billion. When all policy changes are considered together, payments to ESRD facilities are expected to increase by 3.1 percent in 2013.

...

 
Large waist gives survival advantage in heart failure patients. PDF Print
EurekAlert: A slim waist and normal weight are usually associated with better health outcomes, but that's not always the case with heart failure patients, according to a new UCLA study. Researchers found that in both men and women with advanced heart failure, obesity — as indicated by a high body mass index (BMI) — and a higher waist circumference were factors that put them at significantly less risk for adverse outcomes. The study findings are published in the July 1 online issue of the American Journal of Cardiology.

...

 
<< Start < Prev 491 492 493 494 495 496 497 498 499 500 Next > End >>

Page 497 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.